Gaudium IVF Q2 FY27 Results and IPO Objects Variation
Gaudium IVF and Women Health Ltd · Others (Uncategorized) · 13 Nov 2026, 2:49 am
Gaudium IVF Q2 FY27 Results and IPO Objects Variation Gaudium IVF reported consolidated Q2 FY27 revenue from operations of ₹3,741.11 lakhs, up 17.90% YoY from ₹3,173.04 lakhs, and PAT of ₹941.31 lakhs compared to ₹937.91 lakhs in Q2 FY26. Sequentially, PAT surged 430.05% QoQ from ₹177.59 lakhs. The Board approved a variation to substitute 6 locations and extend timelines to FY29 for establishing 19 IVF centres, keeping the ₹5,000.00 lakhs allocation unchanged. Dr. Ravish Manchanda was appointed as National Head – Operations Expansion & Strategy. Unutilized IPO proceeds stood at ₹3,988.04 lakhs as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Gaudium IVF and Women Health Ltd
- Gaudium IVF and Women Health Limited has informed the Exchange about audio recording of Earnings Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half .... · 17 Nov 2026
- Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026 · 15 Nov 2026
- Rectification of inadvertent typographical error in the unaudited consolidated financial results for the quarter and half year ended September 30,2026 · 13 Nov 2026
- Monitoring Agency Report for quarter ended September 30, 2026 · 13 Nov 2026
- Gaudium IVF and Women Health Limited has informed the Exchange regarding revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information pursuant to Regulation 8(2) of SEBI (PIT) Regulations, 2015. · 13 Nov 2026
- Revised Code of Practices and Procedures for fair Disclosure of Unpubulished Price Sensitive Information Pursuant to Regulation 8(2) of SEBI (PIT) Regulations, 2015. · 13 Nov 2026
- Gaudium IVF and Women Health Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · 13 Nov 2026
- Press Release on the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2026 · 13 Nov 2026
